New targeted pill combo for advanced colon or stomach cancers
Part of Cancer, Digestive system clinical trials.
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon (CRC) or stomach/gastroesophageal (EGC) adenocarcinoma that has spread or is locally advanced
- You’ve tried at least one prior treatment, and it either stopped working or you couldn’t tolerate it
- Your cancer has measurable tumors on scans (the study team must be able to track changes)
- You should be able to do daily activities fairly well (ECOG performance status 0–1)
- Your blood counts and organ tests must be in safe ranges (low hemoglobin/neutrophils/platelets, or major liver/kidney problems may exclude you)
- You must be able to swallow pills and agree to contraception if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in people with colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases) and who have already had surgery to remove as much cancer as possible. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
Hear when a new Locally Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.